Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, Canadian researchers have found. However, there is a very different perception among doctors, who consider that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.